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Abstract
Background: HIV-1 infects the central nervous system (CNS) shortly after transmission. This leads to a chronic
intrathecal immune activation. YKL-40, a biomarker that mainly reflects activation of astroglial cells, has not been
thoroughly investigated in relation to HIV. The objective of our study was to characterize cerebrospinal fluid (CSF)
YKL-40 in chronic HIV infection, with and without antiretroviral treatment (ART).
Methods: YKL-40, neopterin, and the axonal marker neurofilament light protein (NFL) were analyzed with ELISA in
archived CSF samples from 120 HIV-infected individuals (85 untreated neuroasymptomatic patients, 7 with HIV-
associated dementia, and 28 on effective ART) and 39 HIV-negative controls.
Results: CSF YKL-40 was significantly higher in patients with HIV-associated dementia compared to all other
groups. It was also higher in untreated neuroasymptomatic individuals with CD4 cell count < 350 compared to
controls. Significant correlations were found between CSF YKL-40 and age (r = 0.38, p < 0.001), CD4 (r = − 0.36, p < 0.
001), plasma HIV RNA (r = 0.35, p < 0.001), CSF HIV RNA (r = 0.35, p < 0.001), CSF neopterin (r = 0.40, p < 0.001), albumin
ratio (r = 0.44, p < 0.001), and CSF NFL (r = 0.71, p < 0.001). Age, CD4 cell count, albumin ratio, and CSF HIV RNA were
found as independent predictors of CSF YKL-40 concentrations in multivariable analysis. In addition, CSF YKL-40 was
revealed as a strong independent predictor of CSF NFL together with age, CSF neopterin, and CD4 cell count.
Conclusions: CSF YKL-40 is a promising biomarker candidate for understanding the pathogenesis of HIV in the CNS.
The strong correlation between CSF YKL-40 and NFL suggests a pathogenic association between astroglial activation
and axonal injury, and implies its utility in assessing the prognostic value of YKL-40.
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Background
Like other lentiviruses, HIV-1 (henceforth HIV) is a
neurotropic virus. It enters the central nervous system
(CNS) early after transmission and persists throughout
the course of infection [1]. After traversing the
blood-brain barrier (BBB), HIV productively infects peri-
vascular macrophages and microglia, leading to an in-
flammatory response with the activation of these cells
[2]. The infected cells produce viral particles and release
viral proteins and cellular products such as cytokines,
quinolinic and arachidonic acid, platelet-activating factor,
and nitric oxide, all of which are toxic against neurons
and astrocytes [3]. Astrocytes can also be infected, al-
though to a lesser extent than monocytic cells, and prob-
ably not productively, but they can be activated by
microglia [4, 5]. Proliferation of astrocytes (astrogliosis) is
one of the neuropathological hallmarks of HIV-associated
dementia (HAD). Astrocyte activation is also linked to in-
creased permeability of the BBB, which enhances the leak-
age of cells and serum products into the CNS [6]. HIV
does not productively infect neurons, but an intrathecal
inflammation is associated with synaptodendritic injury,
neuronal dysfunction, and apoptosis [7]. Although the
exact pathogenesis remains uncertain, previous studies
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have indicated that the above inflammation is mediated by
infected macrophages and microglia interacting with as-
trocytes [8]. This immune activation, perhaps in combin-
ation with toxic metabolites from immune cells and viral
proteins, may be the driver of neuronal injury in HIV in-
fection [9].
Before effective antiretroviral treatment (ART) was
available, up to 30% of people living with HIV (PLHIV)
developed HAD with cognitive and motor impairment
[3]. The prevalence of HAD dramatically decreased after
the introduction of combination ART. However, despite
effective ART, milder forms of HIV-associated neurocog-
nitive disorders (HAND) are still frequently reported
among PLHIV, impacting neurocognitive function and
quality of life [10, 11].
Neopterin is a marker of intrathecal immune activa-
tion that has been thoroughly studied in relation to HIV
[12–16]. It is mainly produced by macrophages and re-
lated cells, such as dendritic cells, after stimulation by
interferon gamma (IFN-γ) and tumor necrosis factor
alpha (TNFα) from activated T cells [12, 13]. Cerebro-
spinal fluid (CSF) concentrations of neopterin increase
in all stages of untreated HIV infection, with the highest
levels seen in patients with CNS opportunistic infections
and HAD [14]. Neopterin levels decrease substantially
after treatment initiation but remain above normal refer-
ence levels in approximately 40% of PLHIV with effect-
ive ART [15, 16]. A correlation between neopterin and
axonal injury, as measured by CSF neurofilament light
protein (NFL), has been found, supporting the hypoth-
esis of neuroinflammation as a cause of CNS injury in
PLHIV [16].
YKL-40 (chitinase-3-like protein 1 [CHI3L1]) is a glyco-
protein expressed by inflammatory cells during differenti-
ation [17]. Elevated serum levels of YKL-40 have been
found in several inflammatory diseases and malignancies
[17–20]. The physiological role of YKL-40 is unclear, but
it is believed to be involved in tissue remodeling in inflam-
mation [21]. YKL-40 levels in CSF are elevated particularly
in neurodegenerative and neuroinflammatory diseases
such as Alzheimer’s disease [22] and multiple sclerosis
(MS) [23, 24]. While expressed by microglia and macro-
phages in vitro, YKL-40 has been seen to accumulate
around activated astrocytes in vivo [25, 26]. The expres-
sion of YKL-40 in neuroinflammation appears to be re-
lated primarily to astrocyte activation induced by
interleukin 1 beta (IL-1β) and TNFα released by macro-
phages [26, 27]; however, the exact contribution from dif-
ferent cell types has not been fully elucidated.
Increased levels of CSF YKL-40, but not plasma YKL-40,
have previously been found in macaques with simian im-
munodeficiency virus (SIV) 2–8weeks before development
of encephalitis [28]. In humans, initiation of ART was asso-
ciated with lower CSF YKL-40 concentrations in acute,
but not in chronic, HIV. This could indicate that it is pos-
sible to prevent or decrease intrathecal immune activation
by early initiation of ART [29].
The objective of this study was to determine CSF
YKL-40 in different stages of chronic HIV infection, with
and without ART, and to investigate how it relates to
axonal injury, as measured by CSF NFL, for better un-
derstanding of the HIV neuropathogenesis.
Methods
Patients
In this retrospective, cross-sectional study, we analyzed
archived CSF samples from 120 PLHIV followed at the
Department of Infectious Diseases, Sahlgrenska Univer-
sity Hospital, Gothenburg, Sweden, and from 39
HIV-negative controls. The HIV-infected individuals
were divided into three groups: (1) neuroasymptomatic
(NA) without ART (n = 85), further stratified into four
categories according to CD4+ T cell count; (2) HAD,
without ART (n = 7); and (3) patients on suppressive
ART (n = 28). The diagnosis of HAD was based on the
Centers for Disease Control and Prevention and Ameri-
can Academy of Neurology task force criteria using
standard laboratory, neuropsychological testing, and
clinical evaluations [30, 31]. Patient characteristics are
presented in Table 1. Controls were healthy volunteers
(69% men) with a median age of 40 years (Table 1)
Laboratory analysis
Low-speed centrifugation was used to remove cells from
CSF and blood samples. They were then aliquoted and
frozen to − 70 °C within 1 h of obtaining the samples by
lumbar puncture and stored until analysis.
CSF and serum YKL-40 levels were measured by
solid-phase sandwich ELISA (R&D Systems, Minneapolis,
MN, USA) with a lower detection limit of 2.32 pg/mL.
CSF NFL was measured using a sandwich ELISA
method (NF-light® ELISA kit, UmanDiagnostics, AB,
Umeå, Sweden). The lower limit of quantification was
50 ng/L. Upper reference values are age dependent as
described by Yilmaz et al. [32].
HIV RNA in CSF and plasma was measured using the
Roche Amplicor Monitor version 1.5 or Roche TaqMan
assay version 1 or 2 with lower quantification limits of 50
and 20 copies/mL, respectively (Hoffman La-Roche, Basel,
Switzerland).
Neopterin was analyzed in CSF and serum using a
commercially available immunoassay (BRAHMS, Berlin,
Germany) with an upper normal limit of 5.8 nmol/L in
CSF and 8.8 nmol/L in serum [14, 15].
Other measurements, including blood CD4+ T cell
counts, CSF white blood cells (WBC), and CSF and blood
albumin, were performed in the local clinical laboratory
using standard clinical chemistry assays. Albumin ratio
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was calculated as CSF albumin (mg/L)/plasma albumin
(g/L) and used to evaluate BBB function. Reference values
were < 6.8 for individuals younger than 45 years and <
10.2 for individuals 45 years and older.
Statistical analysis
Descriptive statistics were performed using SPSS software
(IBM SPSS version 24) or Prism (GraphPad software ver-
sion 7.0). Continuous variables, except age and CSF
leukocyte count, were log10 transformed. To compare
continuous variables between multiple groups, one-way
analysis of variance with Tukey’s multiple comparison was
used. Correlations were analyzed with Pearson correlation
coefficients. Predictors of YKL-40 and CSF NFL were ana-
lyzed by multiple linear regression analysis with forward
selection.
Results
CSF YKL-40 concentrations were significantly higher in
patients with HAD, as compared to all other groups
Table 1 Group characteristics
NA neuroasymptomatic, HAD HIV-associated dementia, IQR interquartile range
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(Fig. 1 and Tables 1 and 2). NA patients in all CD4+ T
cell count strata < 350 cells/μL had significantly higher
levels of CSF YKL-40 compared to HIV-negative controls,
while CSF YKL-40 in NA patients with CD4+ T cell count
> 350 did not differ significantly from controls.
Serum YKL-40 was available for 120 individuals: 5
were HAD patients, 82 were NA, 28 were on ART, and
5 were controls. The mean serum levels of YKL-40 were
27% lower than CSF levels. There was a weak correlation
between serum and CSF YKL-40 (r = 0.26, p < 0.01), but
serum YKL-40 was not found to be a significant pre-
dictor of CSF YKL-40 or NFL in multivariable analyses
(Fig. 2 and Table 3).
When analyzing PLHIV with and without ART, we
found significant correlations between CSF YKL-40 and
age, CD4+ T cell count, CSF HIV RNA, CSF neopterin,
albumin ratio, and CSF NFL (Table 4 and Fig. 3).
When analyzing only people with effective ART, CSF
YKL-40 correlated significantly with age (r = 0.58, p =
0.001), CSF neopterin (r = 0.38, p < 0.05), and CSF NFL
(r = 0.375, p < 0.05).
In untreated PLHIV, including both NA individuals and
patients with HAD, a significant correlation was found be-
tween CSF YKL-40 and age (r = 0.41, p < 0.001), CSF neop-
terin (r = 0.34, p = 0.001), albumin ratio (r = 0.45, p < 0.001),
and CSF NFL (r = 0.73, p < 0.001). There was a significant
negative correlation between YKL-40 and CD4+ T cell
count (r = − 0.36, p < 0.001).
In controls, we found a significant correlation between
CSF YKL-40 and age (r = 0.60, p < 0.001), albumin ratio
(r = 0.43, p < 0.05), and CSF NFL (r = 0.68, p < 0.001).
CD4+ T cell count and neopterin were not analyzed in
the controls.
Age, CD4+ T cell count, albumin ratio, and CSF HIV
RNA stood out as independent predictors of CSF
YKL-40 concentrations in a multivariable analysis, in-
cluding participants from all HIV groups (Table 4).
In addition, CSF YKL-40 was shown to be a strong in-
dependent predictor of CSF NFL in a multivariable ana-
lysis, together with age, CSF neopterin, and CD4+ T cell
count (Table 5).
Discussion
Astrocytes are considered important in the pathogenesis of
HAD. Chronic intrathecal immune activation leads to im-
pairment of the astrocytes’ physiological and neuronal sup-
port functions, and also to activation and proliferation of
astrocytes [4]. We found that CSF levels of YKL-40, a
marker of astrocytic activation, are significantly elevated in
patients with HAD, compared to individuals on suppressive
ART and to untreated NA individuals, irrespective of CD4+
T cell count. NA individuals with low CD4+ T cell counts
(< 350 cells/μL) had significantly higher CSF YKL-40 com-
pared to HIV-negative controls, but individuals with a pre-
served immune system (CD4 > 350 cells/μL) had CSF
YKL-40 in the same range as controls. These findings sup-
port the conclusion that the activation of astrocytes is in-
volved in HIV neuropathogenesis and in the development
of HAD, as previously proposed by others [4, 5, 33].
One of our main findings is the strong correlation be-
tween CSF YKL-40 and CSF NFL, a sensitive marker of
axonal injury [34, 35] indicating that there is an associ-
ation between astrocytic activation and axonal injury.
This is in agreement with a previous study with a correl-
ation between CSF levels of YKL-40 and NFL in patients
with chronic untreated HIV [29]. Correlations between
YKL-40 and NFL have also been seen in MS [36]. In
addition, we found albumin ratio to be an independent
predictor of YKL-40. BBB disruption is mainly found in
individuals with HAD and is thought of as a critical
event in HIV CNS infection. Previous studies have also
found that CSF neopterin and albumin ratio are inde-
pendent predictors of CSF NFL, pointing towards a
complex interplay between the activation of cells in the
Fig. 1 Group comparisons of CSF (cerebrospinal fluid) levels of a YKL-40, b neopterin, and c NFL. Boxes in panels depict median and IQR,
whiskers show 10–90 percentiles, and the plus sign designates the means
Hermansson et al. Journal of Neuroinflammation           (2019) 16:16 Page 4 of 9
CNS, dysfunction of the BBB, and axonal injury in the
pathogenesis of HIV in the CNS [37]. This further sup-
ports earlier findings suggesting that astrocyte activation
is a major factor in this interaction and in the neuro-
pathogenesis of HAD.
A similar pattern to that which we found for CSF
YKL-40 has previously been reported for CSF neopterin
during HIV infection [14]. Neopterin in CSF is probably
the most studied marker of monocytic activation in HIV
CNS infection. It is mainly produced by macrophages and
microglial cells, but it can also be made by astrocytes, after
stimulation with IFN-γ [38, 39]. Consequently, increased
CSF neopterin concentrations probably reflect a multi-
modal activation of several different cell types. CSF neop-
terin levels are elevated early in HIV infection and remain
elevated during all stages of infection, with the highest
levels in individuals with HAD and CNS opportunistic in-
fections. After initiation of ART, CSF neopterin decreases
markedly but remains slightly abnormal in a large number
of patients, despite several years of receiving ART [15].
CSF YKL-40 differs from neopterin in several ways.
Neopterin is a small (253 Da) pteridine and YKL-40 is a
40 kDa protein. Although there is a possible overlap, as
already mentioned, they largely represent the activation
of different cell types. These are mainly macrophages
and microglia for neopterin and astrocytes for YKL-40.
We found a significant correlation between CSF YKL-40
and CSF neopterin among all HIV-infected individuals,
whether or not they had neurocognitive impairment, or
were or were not on ART. In a previous study [29], CSF
YKL-40 correlated with neopterin in chronic, but not in
acute HIV infection. The fact that the two biomarkers
have different origins, or perhaps different mechanisms
or time points leading to activation of the cellular
Table 2 Median cerebrospinal fluid biomarker levels for the different groups of participants
CSF cerebrospinal fluid, IQR interquartile range, ND no data
Fig. 2 Correlation between serum and CSF (cerebrospinal fluid) YKL-
40 in 115 HIV-positive patients and 5 controls, using the Pearson
correlation coefficient
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sources, might explain some of the results in both of the
studies. Although CSF YKL-40 does not have much clin-
ical utility when compared to CSF neopterin, it is im-
portant to study various biomarkers that reflect different
inflammatory pathways and activation of different cell
types.
Soluble triggering receptor expressed on myeloid cells 2
(sTREM2) is a receptor glycoprotein belonging to the im-
munoglobulin superfamily. It is more specific for activa-
tion of microglia and macrophages than neopterin, since
the secreted form of the receptor is exclusively expressed
on myeloid cells such as macrophages and microglia, but
not on astrocytes. It has become an established CSF bio-
marker selective for microglial activation and studied
mainly in Alzheimer’s disease. In HIV infection, CSF con-
centrations of sTREM2 have been shown to be highest in
patients with HAD and to increase in NA untreated indi-
viduals as the immune deficiency progresses [40].The
same study also found a strong correlation between CSF
sTREM2 concentrations and CSF NFL. It would be of
interest to also study other inflammatory biomarkers and
Table 3 Comparing group levels of CSF YKL-40, neopterin, and NFL using Tukey’s multiple comparison test after one-way ANOVA
Group comparisons CSF YKL-40 (log) CSF neopterin (log) CSF NFL (log)
Overall ANOVA p
< 0.0001 < 0.0001 < 0.0001
Tukey’s multiple comparison
HAD vs. HIV– < 0.0001 ND < 0.0001
HAD vs. ART < 0.0001 < 0.0001 < 0.0001
HAD vs. NA CD4 ≥ 350 < 0.0001 < 0.0001 < 0.0001
HAD vs. NA CD4 200–349 < 0.0001 ns < 0.0001
HAD vs. NA CD4 50–199 < 0.0001 ns < 0.0001
HAD vs. NA CD4 < 50 < 0.0001 ns < 0.0001
NA CD4 < 50 vs. HIV– < 0.0001 ND < 0.0001
NA CD4 < 50 vs. ART < 0.05 < 0.0001 < 0.0001
NA CD4 < 50 vs. NA CD4 ≥ 350 < 0.05 < 0.0001 < 0.0001
NA CD4 < 50 vs. NA CD4 200–349 ns ns < 0.0001
NA CD4 < 50 vs. NA CD4 50–199 ns ns ns
NA CD4 50–199 vs. HIV– < 0.0001 ND ns
NA CD4 50–199 vs. ART ns < 0.0001 < 0.05
NA CD4 50–199 vs. NA CD4 ≥ 350 ns < 0.01 ns
NA CD4 50–199 vs. NA CD4 200–349 ns ns ns
NA CD4 200–349 vs. HIV– < 0.05 ND ns
NA CD4 200–349 vs. ART ns < 0.0001 ns
NA CD4 200–349 vs. NA CD4 ≥ 350 ns < 0.05 ns
NA CD4 ≥ 350 vs. HIV– ns ND ns
NA CD4 ≥ 350 vs. ART ns < 0.01 ns
ART vs. HIV– ns ND ns
Median cerebrospinal (CSF) levels of YKL-40, neopterin, and NFL for the different groups
IQR interquartile range, ND no data, ns not significant, NA neuroasymptomatic, HAD HIV-associated dementia, ART antiretroviral therapy
Table 4 Predicting cerebrospinal fluid YKL-40
Predictor Univariable Multivariable
Std b (r) p Std badj p
Age 0.378 < 0.001 0.418 < 0.001
CD4+ T cell count − 0.380 < 0.001 − 0.285 0.002
Plasma HIV RNA 0.349 < 0.001
CSF HIV RNA 0.350 < 0.001 0.298 0.005
Serum neopterin 0.287 0.002
CSF neopterin 0.401 < 0.001
Albumin ratio 0.435 < 0.001 0.223 0.004
Serum YKL-40 0.227 0.015
Univariable correlation (left columns) and multiple linear regression (right
columns) determining predictors of log10 CSF YKL-40 in 120 HIV-infected patients
CSF cerebrospinal fluid
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their association with YKL-40 and NFL. In a recent
meta-analysis, CSF TGF-ß, MCP-1, and YKL-40 levels
were significantly elevated in patients with neurodegener-
ative diseases such as Alzheimer’s disease, Parkinson’s dis-
ease, and amyotrophic lateral sclerosis [41].
Other markers of astrocytic activation have been sug-
gested for studies in HIV. Glial fibrillary acidic protein
(GFAP) is a major structural protein of astrocytes. Like
YKL-40, CSF levels of GFAP increase in conditions with
astrogliosis, such as Alzheimer’s disease and MS. There
was no difference in CSF GFAP concentrations in indi-
viduals with HAD compared with individuals who had
opportunistic CNS infections, HIV-infected NA individ-
uals, or HIV-negative controls [42, 43]. Another astro-
cyte marker is S100β, an acidic calcium-binding protein
that is abundant in astrocytes. CSF levels of S100β have
previously been shown to be significantly higher in pa-
tients with moderate to severe HAD (formerly called
AIDS dementia complex stages 2–3) than in patients
with mild (stage 1) or no dementia. In addition, CSF
S100β levels were higher in individuals with moderate to
severe dementia who succumbed to their disease more
rapidly than those who deteriorated more slowly with
the same dementia stage [44]. It has not been shown to
be useful in distinguishing HAD patients from patients
with other neurological conditions [45], nor has it, to
the best of our knowledge, been investigated in relation
to NFL.
YKL-40 found in CSF is most likely produced in the
CNS rather than in the periphery. We found a signifi-
cant but weak correlation between CSF and serum
YKL-40 concentrations. Serum levels of YKL-40 were
27% lower than CSF levels and were not shown to pre-
dict CSF YKL-40 in multivariable analysis. A similar lack
of independent association between serum and CSF
YKL-40 has previously been demonstrated in Alzhei-
mer’s disease [22].
This study has several limitations. While the overall
number of subjects was relatively large, individual
groups were limited in size. The important HAD group
was especially restricted by low incidence and availability
making it difficult to draw conclusions about this group.
Neurocognitive performance testing was not consistently
done in non-HAD patients, making it impossible to
evaluate CSF YKL-40 in patients with milder forms of
HAND, such as asymptomatic neurocognitive impair-
ment and mild neurocognitive disorder. CSF NFL has
previously been suggested as a predictive marker of
HAD [46]. The present study, however, has a retrospect-
ive cross-sectional design. A longitudinal study of CSF
YKL-40 in HIV could further clarify its dynamics before
and after the initiation of ART and perhaps resolve the
efficacy of using YKL-40 as a prognostic marker or a
marker of treatment response as well. Moreover, at a
time where more and more PLHIV are on effective ART,
studying a larger cohort on ART and patients with
milder forms of HAND would be of interest to deter-
mine whether YKL-40 remains a useful marker that cor-
relates with axonal injury in patients on ART. Controls
were healthy volunteers, not matched with respect to
demographic and lifestyle factors which has to be taken
into consideration when interpreting the results [47].
Conclusions
The focus of this study was to evaluate CSF YKL-40 in
HIV-infected individuals with different stages of disease
a b c
Fig. 3 Correlations between CSF concentrations of a YKL-40 and neurofilament light protein (NFL), b neopterin and NFL, and c neopterin and
YKL-40, using the Pearson correlation coefficient
Table 5 Predicting cerebrospinal fluid NFL
Predictor Univariable Multivariable
Std b (r) p Std badj p
Age 0.402 < 0.001 0.203 0.003
CD4+ T cell count − 0.530 < 0.001 − 0.259 < 0.001
CSF HIV RNA 0.348 < 0.001
CSF neopterin 0.498 < 0.001 0.178 0.014
Albumin ratio 0.409 < 0.001
CSF YKL-40 0.710 < 0.001 0.444 < 0.001
Univariable correlation (left columns) and multiple linear regression (right
columns) determining predictors of log10 CSF NFL in 120 HIV-infected patients.
CSF: cerebrospinal fluid
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and with and without ART, and our results conclude
that CSF YKL-40 is a promising candidate biomarker for
understanding the pathogenesis of HIV in the CNS. The
strong correlation between CSF YKL-40 and NFL sug-
gests a pathogenetic association between astroglial acti-
vation and axonal injury and implies utility to evaluate
the value of YKL-40 as a prognostic marker or marker
of treatment response in HIV disease. It would also be
of interest to study CSF YKL-40 longitudinally in indi-
viduals on ART with and without HAND.
Abbreviations
ART: Antiretroviral treatment; BBB: Blood-brain barrier; CNS: Central nervous
system; CSF: Cerebrospinal fluid; GFAP: Glial fibrillary acidic protein; HAD: HIV-
associated dementia; HAND: HIV-associated neurocognitive disorder;
HIV: Human immunodeficiency virus; IFN-γ: Interferon gamma;
NA: Neuroasymptomatic; NFL: Neurofilament light protein; PLHIV: People





This project has received grants from the Swedish State support for Clinical
Research (ALFGBG-717531, ALFGBG-715986, and ALFGBG-720931), the
Swedish Brain foundation (project # FO2017-0243), the National Institutes of
Health (R01 NS094067), the Knut and Alice Wallenberg Foundation, the
Torsten Söderberg Foundation, and the Swedish and European Research
Councils.
Availability of data and materials
The dataset supporting the conclusions of this article is included as an
additional file.
Authors’ contributions
MG, AY, and HZ conceived and designed the study; HZ, MA, DF, and KB
carried out the laboratory analyses; LHe, AY, and MG analyzed and
interpreted the data and drafted the manuscript; LHa, MG, AY, and LHe
collected and organized the data; LHe and MG performed the statistical
analyses. All authors read, reviewed, and approved the final manuscript.
Ethics approval and consent to participate
The study was approved by the Regional Ethics Review Board in
Gothenburg, Sweden (Ö588-01) and was performed in accordance with the




HZ has served on scientific advisory boards for Eli Lilly, Roche Diagnostics,
and Wave; he has received travel grants from Teva; and he is also a co-
founder of Brain Biomarker Solutions in Gothenburg AB, a venture-based
platform company at the University of Gothenburg.
KB has served as a consultant or on advisory boards for Alzheon, BioArctic,
Biogen, Eli Lilly, Fujirebio Europe, IBL International, Merck, Novartis, Pfizer, and
Roche Diagnostics. He is also a co-founder of Brain Biomarker Solutions in
Gothenburg AB, a venture-based platform company at the University of
Gothenburg. The other authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Department of Infectious Diseases, University of Gothenburg, Gothenburg,
Sweden. 2Department of Neurology, University of Gothenburg, Gothenburg,
Sweden. 3Department of Psychiatry and Neurochemistry, Sahlgrenska
Academy, University of Gothenburg, Gothenburg, Sweden. 4Clinical
Neurochemistry Lab, Sahlgrenska University Hospital, Mölndal, Sweden.
5Division of Biological Chemistry, Biocenter, Innsbruck Medical University,
Innsbruck, Austria. 6Institute of Neurology, University College London,
London, UK.
Received: 26 September 2018 Accepted: 9 January 2019
References
1. Valcour V, Sithinamsuwan P, Letendre S, Ances B. Pathogenesis of HIV in the
central nervous system. Curr HIV/AIDS Rep. 2011;8:54–61.
2. Burdo TH, Lackner A, Williams KC. Monocyte/macrophages and their role in
HIV neuropathogenesis. Immunol Rev. 2013;254:102–13.
3. González-Scarano F, Martín-García J. The neuropathogenesis of AIDS. Nat
Rev Immunol. 2005;5:69–81.
4. Brach-Werner R. Astrocytes: HIV cellular reservoirs and important participants
in neuropathogenesis. AIDS. 1999;13:1–22.
5. Ranki A, Nyberg M, Ovod V, Haltia M, Elovaara I, Raininko R, et al. Abundant
expression of HIV Nef and Rev proteins in brain astrocytes in vivo is
associated with dementia. AIDS. 1995;9:1001–8.
6. Eugenin EA, Clements JE, Zink MC, Berman JW. Human immunodeficiency
virus infection of human astrocytes disrupts blood-brain barrier integrity by
a gap junction-dependent mechanism. J Neurosci. 2011;31:9456–65.
7. Ellis R, Langford D, Masliah E. HIV and antiretroviral therapy in the brain:
neuronal injury and repair. Nat Rev Neurosci. 2007;8:33–44.
8. Kaul M, Garden GA, Lipton SA. Pathways to neuronal injury and apoptosis in
HIV-associated dementia. Nature. 2001;410:988–94.
9. Zayyad Z, Spudich S. Neuropathogenesis of HIV: from initial neuroinvasion
to HIV-associated neurocognitive disorder (HAND). Current HIV/AIDS
Reports. 2015;12:16–24.
10. Robertson KR, Smurzynski M, Parsons TD, Wu K, Bosch RJ, Wu J, et al. The
prevalence and incidence of neurocognitive impairment in the HAART era.
AIDS. 2007;21:1915–21.
11. Vivithanaporn P, Heo G, Gamble J, Krentz HB, Hoke A, Gill MJ, et al.
Neurologic disease burden in treated HIV/AIDS predicts survival: a
population-based study. Neurology. 2010;75:1150–8.
12. Fuchs D, Spira TJ, Hausen A, Reibnegger G, Werner ER, Felmayer GW, et al.
Neopterin as a predictive marker for disease progression in human
immunodeficiency virus type 1 infection. Clin Chem. 1989;35:1746–9.
13. Wirleitner B, Reider D, Ebner S, Böck G, Widner B, Jaeger M, et al. Monocyte-
derived dendritic cells release neopterin. J Leukoc Biol. 2002;72:1148–53.
14. Hagberg L, Cinque P, Gisslen M, Brew BJ, Spudich S, Bestetti A, et al.
Cerebrospinal fluid neopterin: an informative biomarker of central nervous
system immune activation in HIV-1 infection. AIDS Res Ther. 2010;7:15.
15. Yilmaz A, Yiannoutsos CT, Fuchs D, Price RW, Crozier K, Hagberg L, et al.
Cerebrospinal fluid neopterin decay characteristics after initiation of
antiretroviral therapy. J Neuroinflammation. 2013;10:62.
16. Edén A, Marcotte TD, Heaton RK, Nilsson S, Zetterberg H, Fuchs D, et al.
Increased intrathecal immune activation in virally suppressed HIV-1 infected
patients with neurocognitive impairment. PLoS One. 2016;11:e0157160.
17. Roslind A, Johansen JS. YKL-40: a novel marker shared by chronic inflammation
and oncogenic transformation. Methods Mol Biol. 2009;511:159–84.
18. Johansen JS, Schultz NA, Jensen BV. Plasma YKL-40: a potential new cancer
biomarker? Future Oncol. 2009;5:1065–82.
19. Johansen J, Stoltenberg M, Hansen M, Florescu A, Horslev-Petersen K,
Lorenzen I, et al. Serum YKL-40 concentrations in patients with rheumatoid
arthritis: relation to disease activity. Rheumatology. 1999;38:618–26.
20. Koutroubakis I, Petinaki E, Dimoulios P, Vardas E, Roussomoustakaki M,
Maniatis A, et al. Increased serum levels of YKL-40 in patients with
inflammatory bowel disease. Int J Color Dis. 2003;18:254–9.
21. Lee CG, Hartl D, Lee GR, Koller B, Matsuura H, Da Silva CA, et al. Role of
breast regression protein 39 (BRP-39)/chitinase 3-like-1 in Th2 and IL-13–
induced tissue responses and apoptosis. J Exp Med. 2009;206:1149–66.
22. Craig-Schapiro R, Perrin RJ, Roe CM, Xiong C, Carter D, Cairns NJ, et al. YKL-
40: a novel prognostic fluid biomarker for preclinical Alzheimer’s disease.
Biol Psychiatry. 2010;68:903–12.
23. Malmeström C, Axelsson M, Lycke J, Zetterberg H, Blennow K, Olsson B. CSF
levels of YKL-40 are increased in MS and replaces with immunosuppressive
treatment. J Neuroimmunol. 2014;269:87–9.
Hermansson et al. Journal of Neuroinflammation           (2019) 16:16 Page 8 of 9
24. Muszynski P, Groblewska M, Kulcynska-Przybik A, Kulakowska A, Mroczko B.
YKL-40 as a potential biomarker and a possible target in therapeutic
strategies of Alzheimer’s disease. Curr Neuropharmacol. 2017;15:906–17.
25. Kolson DL. YKL-40: a candidate biomarker for simian immunodeficiency
virus and human immunodeficiency virus encephalitis? Am J Pathol. 2008;
173:25–9.
26. Bonneh-Barkay D, Wang G, Starkey A, Hamilton RL, Wiley CA. In vivo CHI3L1
(YKL-40) expression in astrocytes in acute and chronic neurological diseases.
J Neuroinflammation. 2010;7:34.
27. Bonneh-Barkay D, Bissel SJ, Kofler J, Starkey A, Wang G, Wiley CA. Astrocyte
and macrophage regulation of YKL-40 expression and cellular response in
neuroinflammation. Brain Pathol. 2012;22:530–46.
28. Bonneh-Barkay D, Bissel SJ, Wang G, Fish KN, Nicholl GCB, Darko SW, et al.
YKL-40, a marker of simian immunodeficiency virus encephalitis, modulates
the biological activity of basic fibroblast growth factor. Am J Pathol. 2008;
173:130–43.
29. Peluso MJ, Valcour V, Phanuphak N, Ananworanich J, Fletcher JLK,
Chalermchai T, et al. Immediate initiation of cART is associated with lower
levels of cerebrospinal fluid YKL-40, a marker of microglial activation, in HIV-
1 infection. AIDS. 2017;31:247–52.
30. Janssen RS, Cornblath DR, Epstein LG, Foa RP, McArthur JC, Price RW, Tross
S. Nomenclature and research case definitions for neurologic manifestations
of human immunodeficiency virus-type 1 (HIV-1) infection. Report of a
Working Group of the American Academy of Neurology AIDS Task Force.
Neurology. 1991;41:778-785.
31. Antinori A, Arendt G, Becker JT, Brew BJ, Byrd DA, Cherner M, et al. Updated
research nosology for HIV-associated neurocognitive disorders. Neurology.
2007;69:1789–99.
32. Yilmaz A, Blennow K, Hagberg L, Nilsson S, Price RW, Schouten J, et al.
Neurofilament light chain protein as a marker of neuronal injury: review of
its use in HIV-1 infection and reference values for HIV-negative controls.
Expert Rev Mol Diagn. 2017;17:761–70.
33. Churchill MJ, Wesselingh SL, Cowley D, Pardo CA, McArthur JC, Brew BJ, et
al. Extensive astrocyte infection is prominent in human immunodeficiency
virus - associated dementia. Ann Neurol. 2009;66:253–8.
34. Krut JJ, Mellberg T, Price RW, Hagberg L, Fuchs D, Rosengren L, et al.
Biomarker evidence of axonal injury in neuroasymptomatic HIV-1 patients.
PLoS One. 2014;9:e88591.
35. Peterson J, Gisslen M, Zetterberg H, Fuchs D, Shacklett BL, Hagberg L, et al.
Cerebrospinal fluid (CSF) neuronal biomarkers across the spectrum of HIV
infection: hierarchy of injury and detection. PLoS One. 2014;9:e116081.
36. Mañé-Martínez MA, Olsson B, Bau L, Matas E, Cobo-Calvo Á, Andreasson U,
et al. Glial and neuronal markers in cerebrospinal fluid in different types of
multiple sclerosis. J Neuroimmunol. 2016;299:112–7.
37. Anesten B, Yilmaz A, Hagberg L, Zetterberg H, Nilsson S, Brew BJ, et al.
Blood-brain barrier integrity, intrathecal immunoactivation, and neuronal
injury in HIV. Neurol Neuroimmunol NeuroInflamm. 2016;3:e300.
38. Fuchs D, Hausen A, Reibnegger G, Werner ER, Dierich MP, Wachter H.
Neopterin as a marker for activated cell-mediated immunity: application in
HIV infection. Immunol Today. 1988;9:150–5.
39. Cano OD, Neurauter G, Fuchs D, Shearer GM, Boasso A. Differential effect of
type I and type II interferons on neopterin production and amino acid
metabolism in human astrocyte-derived cells. Neurosci Lett. 2008;438:22–5.
40. Gisslén M, Heslegrave A, Veleva E, Yilmaz A, Andersson L-M, Hagberg L, et al.
CSF concentrations of soluble TREM2 as a marker of microglial activation in
HIV-1 infection. Neurol Neuroimmunol NeuroInflamm. 2019;6:e512.
41. Chen X, Hu Y, Cao Z, Liu Q, Cheng Y. Cerebrospinal fluid inflammatory
cytokine aberrations in Alzheimer’s disease, Parkinson’s disease and
amyotrophic lateral sclerosis: a systematic review and meta-analysis. Front
Immunol. 2018;19:2122.
42. Sporer B, Missler U, Magerkurth O, Koedel U, Wiesmann M, Pfister HW.
Evaluation of CSF glial fibrillary acidic protein (GFAP) as a putative marker
for HIV-associated dementia. Infection. 2004;32:20–3.
43. Andersson LM, Fredman P, Lekman A, Rosengren L, Gisslén M. Increased
cerebrospinal fluid ganglioside GD3 concentrations as a marker of
microglial activation in HIV type 1 infection. AIDS Res Hum Retrovir. 1998;14:
1065–9.
44. Pemberton LA, Brew BJ. Cerebrospinal fluid S-100β and its relationship with
AIDS dementia complex. J Clin Virol. 2001;22:249–53.
45. Green A, Giovannoni G, Miller R, Harrison M, EJ T. Cerebrospinal fluid S-100b
concentrations in patients with HIV infection. AIDS. 1999;13:130–40.
46. Gisslén M, Hagberg L, Brew BJ, Cinque P, Price RW, Rosengren L. Elevated
cerebrospinal fluid neurofilament light protein concentrations predict the
development of AIDS dementia complex. J Infect Dis. 2007;195:1774–8.
47. Booiman T, Wit FW, Maurer I, De Francesco D, Sabin CA, Harskamp AM, et
al. High cellular monocyte activation in people living with human
immunodeficiency virus on combination antiretroviral therapy and lifestyle-
matched controls is associated with greater inflammation in cerebrospinal
fluid. Open Forum Infect Dis. 2017;4:ofx108.
Hermansson et al. Journal of Neuroinflammation           (2019) 16:16 Page 9 of 9
